Acute Tumor Response to ZD6126 Assessed by Intrinsic Susceptibility Magnetic Resonance Imaging

Carmeliet, 2003, Angiogenesis in health and disease, Nat Med, 9, 653, 10.1038/nm0603-653 Tozer, 2002, The biology of the combretastatins as tumour vascular targeting agents, Int J Exp Pathol, 83, 21, 10.1046/j.1365-2613.2002.00211.x Denekamp, 1982, Endothelial-cell proliferation in experimental tumours, Br J Cancer, 46, 711, 10.1038/bjc.1982.263 Carmeliet, 2000, Angiogenesis in cancer and other diseases, Nature, 407, 249, 10.1038/35025220 Dark, 1997, Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature, Cancer Res, 57, 1829 Chaplin, 1999, Tumour vasculature as a target for cancer therapy, Br J Cancer, 80, 57 Wachsberger, 2003, Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction, Clin Cancer Res, 9, 1957 Siemann, 2004, Vascular-targeting therapies for treatment of malignant disease, Cancer, 100, 2491, 10.1002/cncr.20299 Goto, 2002, Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice, Cancer Res, 62, 3711 Siemann, 2002, Enhancement of radiation therapy by the novel vascular targeting agent ZD6126, Int J Radiat Oncol Biol Phys, 53, 164, 10.1016/S0360-3016(02)02742-6 Blakey, 2002, Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models, Clin Cancer Res, 8, 1974 Davis, 2002, ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature, Cancer Res, 62, 7247 Goertz, 2002, High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow, Cancer Res, 62, 6371 Robinson, 2003, Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging, Br J Cancer, 88, 1592, 10.1038/sj.bjc.6600926 Evelhoch, 2004, Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126, Clin Cancer Res, 10, 3650, 10.1158/1078-0432.CCR-03-0417 McIntyre, 2004, Single dose of the antivascular agent, ZD6126 (N-acetylcolchinol-O-phosphate), reduces perfusion for at least 96 hours in the GH3 prolactinoma rat tumor model, Neoplasia, 6, 150, 10.1593/neo.03247 Horsman, 2003, Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response, Int J Radiat Oncol Biol Phys, 57, 1047, 10.1016/S0360-3016(03)00769-7 Micheletti, 2003, Vascular-targeting activity of ZD6126, a novel tubulin-binding agent, Cancer Res, 63, 1534 Gillies, 2000, Applications of magnetic resonance in model systems: tumor biology and physiology, Neoplasia, 2, 139, 10.1038/sj.neo.7900076 Evelhoch, 2000, Applications of magnetic resonance in model systems: cancer therapeutics, Neoplasia, 2, 152, 10.1038/sj.neo.7900078 Workman, 1998, United Kingdom Coordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia, Br J Cancer, 77, 1, 10.1038/bjc.1998.1 Prysor-Jones, 1981, Effect of bromocriptine on DNA synthesis, growth and hormone secretion of spontaneous pituitary tumours in the rat, J Endocrinol, 88, 463, 10.1677/joe.0.0880463 Howe, 1999, Flow and oxygenation dependent (FLOOD) contrast MR imaging to monitor the response of rat tumors to carbogen breathing, Magn Reson Imaging, 17, 1307, 10.1016/S0730-725X(99)00089-2 Robinson, 2001, Effects of different levels of hypercapnic hyperoxia on tumour R2* and arterial blood gases, Magn Reson Imaging, 19, 161, 10.1016/S0730-725X(01)00230-2 Kostourou, 2003, Effects of overexpression of dimethylarginine dimethylaminohydrolase on tumor angiogenesis assessed by susceptibility magnetic resonance imaging, Cancer Res, 63, 4960 Altman, 1999 Yablonskiy, 1994, Theory of NMR signal behavior in magnetically inhomogeneous tissues: the static dephasing regime, Magn Reson Med, 32, 749, 10.1002/mrm.1910320610 Howe, 2001, Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours, NMR Biomed, 14, 497, 10.1002/nbm.716 Tozer, 2001, Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability, Cancer Res, 61, 6413 Gross, 2003, Monitoring photodynamic therapy of solid tumors online by BOLD-contrast MRI, Nat Med, 9, 1327, 10.1038/nm940 Robinson, 2003, Tumor vascular architecture and function evaluated by non-invasive susceptibility MRI methods and immunohistochemistry, J Magn Reson Imaging, 17, 445, 10.1002/jmri.10274 Rodrigues, 2004, Tumor R2* is a prognostic indicator of acute radiotherapeutic response in rodent tumors, J Magn Reson Imaging, 19, 482, 10.1002/jmri.20024 Kostourou, 2004, Overexpression of dimethylarginine dimethyl-aminohydrolase enhances tumor hypoxia: an insight into the relationship of hypoxia and angiogenesis in vivo, Neoplasia, 6, 401, 10.1593/neo.04109 Taylor, 2003, Evaluation of prostate gland hypoxia with quantified BOLD MRI: initial results from a correlated histological study, Proc Int Soc Magn Reson Med, 11, 531 Jain, 1988, Determinants of tumor blood flow: a review, Cancer Res, 48, 2641 Punwani, 1998, MRI measurements of cerebral deoxyhaemoglobin concentration [dHb]—correlation with near infrared spectroscopy (NIRS), NMR Biomed, 11, 281, 10.1002/(SICI)1099-1492(199810)11:6<281::AID-NBM529>3.0.CO;2-6 Bradley, 1993, MR appearance of hemorrhage in the brain, Radiology, 189, 15, 10.1148/radiology.189.1.8372185 Yamada, 1992, Evaluation of the susceptibility effect on gradient echo phase images in vivo: a sequential study of intracerebral hematoma, Magn Reson Imaging, 10, 559, 10.1016/0730-725X(92)90007-M Rijpkema, 2002, Effects of breathing a hyperoxic hypercapnic gas mixture on blood oxygenation and vascularity of head-and-neck tumors as measured by magnetic resonance imaging, Int J Radiat Oncol Biol Phys, 53, 1185, 10.1016/S0360-3016(02)02825-0 Padhani, 2003, MRI for evaluating antivascular cancer treatments, Br J Radiol, 76, S60, 10.1259/bjr/15334380